All News

colitis.jpg

Ustekinumab Efficacy in Ulcerative Colitis

d Jack Cush, MD

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.

Read Article
GPA.jpg

FDA Approves Rituximab for Children with GPA

d Jack Cush, MD

The U.S. Food and Drug Administration has approved Rituxan (rituximab) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.

This is the first approved treatment for children with vasculitis.

Read Article
podcastLogo-01%20RESIZED.jpg

RheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.

Read Article
narcotics_0.jpg

MMWR: Increased Opioid Use in Lupus

d Jack Cush, MD

Opioids are generally not indicated for pain in systemic lupus erythematosus (SLE) and other rheumatic diseases because of limited efficacy and risks for preference and adverse health effects.

Read Article
IL-2 inhibitor (keep)

Low Dose IL-2 Effective in Lupus

d Jack Cush, MD

A double-blind, placebo-controlled clinical trial of low-dose IL-2 in patients with systemic lupus erythematosus (SLE) has shown that low-dose IL-2 induced was clinically effective while expandng regulatory T cells and NK cells, which may benefit immune homeostasis in SLE patients.

Read Article
CBD2.hemp_.jpg

Arthritis Foundation Releases First CBD Guidance for Adults With Arthritis

d Jack Cush, MD

As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.

Read Article
Retrospective claims study shows that higher ACPA and RF titers were independently associated with 60-78% increased mortality in established RA; the association persisted in when Rx with DMARDs, but not with biologics. https://t.co/hHJx4alNIQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 101 RA pts w/ baseline Cardiac CT; after median of 83 mos, 48% had progression of plaque; predicted by older age, inflammation & prednisone (p<0.05). Coronary Art. Calcium progressors were older, obese, HTN w/ more inflammation https://t.co/hJRhfja0yk

Links:

Dr. John Cush RheumNow ( View Tweet)

Tofacitinib therapy is being studied (not yet approved) in several dermatologic conditions - psoriasis, alopecia areata/universalis, vitiligo, atopic dermatitis and dermatomyositis. https://t.co/Ez3u95Eh7K

Links:

Dr. John Cush RheumNow ( View Tweet)

A&R reviews the inflammasome in autoimmune diseases. Pattern recognition recpt induce inflammasome activation, pro-caspase-1 converts to caspase-1 convertin pro-IL-1β and pro-IL-18 active IL-1β and IL-18; seen in RA, SLE, gout, Sjogrens https://t.co/JGadiEWQWf

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC advises against vaping with marijuana, noting that up to 77% of 805 cases and 12 deaths from lung disease tied to vaping with THC https://t.co/dtDvMJ1dlA

Links:

Dr. John Cush RheumNow ( View Tweet)

Survey for Rheumatologists - You would use an MRI in an RA to assess what?

Dr. John Cush RheumNow ( View Tweet)

5-factor score for mortality in ANCA-associated vasculitis. I’ve never seen a worse Kaplan-Meier survival curve for those with a score of 5! @philseo #CCRwest 😬☠️ https://t.co/utK7avZ0F1
Jeff Sparks jeffsparks ( View Tweet)
The RheumNow Podcast is up - Watch it here>> https://t.co/PolTYQqbBW or listen to the podcast on iTunes, or SoundCloud>> https://t.co/ILQQw2kpse

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - discussing PSS & Cancer, SLE & narcotics, AAV & Lipids, Anakinra & NIDDM. Watch it here>> https://t.co/PolTYQqbBW or listen to the podcast on iTunes, or SoundCloud>> https://t.co/ILQQw2kpse

Links:

Dr. John Cush RheumNow ( View Tweet)

TIF1-γ antibodies may be associated with dermatomyositis and are found in between 13 – 31% of adults and 22 – 29% of children. TIF1-γ antibodies have a strong association with malignancy, esp in patients over the age of 39. https://t.co/0o2VfNwbZC

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Rob Speira & HSS investigators will lead a multicenter, phase II, 6 mos clinical trial of anti-GM-CSF (mavrilimumab) in patients with giant cell arteritis (GCA. There is still heavy reliance on steroids in GCA; tocilizumab was FDA approved in in 2017 https://t.co/zDWgSVuXec

Links:

Dr. John Cush RheumNow ( View Tweet)

Question for Rheumatologists - How do you scoreboard your performance as a Rheumatologist?

Dr. John Cush RheumNow ( View Tweet)

41 participants with RA and T2D were randomised to recv anakinra or a TNFi; RA dz activity decreased in both groups over 6 mos. Anakinra significantly improved A1C at 3 and 6 mos, but TNFi did not. https://t.co/UIBsRjMbKR

Links:

Dr. John Cush RheumNow ( View Tweet)

JAMA study shows inconsistencies and inaccuracies in EMR documentation of ROS and PE findings compared to observer audible recorded observations - study of 9 ED Residents, 30 pt encounters each, total of 180 ED patients. https://t.co/PttGYvgCue

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×